Jinkui Shenqi Wan alleviates doxorubicin-induced renal senescence and injury: insights from network pharmacology and serum UHPLC-MS/MS
Frontiers in Cell and Developmental Biology · 18.11.2026 · 14
DOI: 10.3389/fcell.2026.2010658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 18.11.2026. Verfasst von Shan Zhang und 4 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Renal cellular senescence drives progressive fibrosis and raises the risk of end-stage renal disease in chronic kidney disease (CKD). Jinkui Shenqi Wan (JKSQW) is a classical eight-herb Chinese formula with a long history of use in tonifying kidney essence and delaying aging. However, the core anti-senescent components and key mechanisms of Jinkui Shenqi Wan remain unclear.
Methods
To evaluate JKSQW in vivo , we established a doxorubicin-induced senescence mouse model and assessed renal function, histopathology, and senescence markers (serum creatinine, BUN, proteinuria, urinary RBCs, SA-β-gal, p16/p21). Active components were screened from TCMSP (OB ≥ 30%, DL ≥ 0.18) and intersected with CKD- and aging-related targets from GeneCards and OMIM. UHPLC-MS/MS profiled JKSQW and identified blood-absorbed prototypes; their targets underwent GO/KEGG enrichment. Molecular docking assessed oxypaeoniflorin binding to 13 core PPI targets. Exosome-like nanoparticles from Moutan Cortex (MDP-Exo) were isolated and evaluated in doxorubicin-treated podocytes using SA-β-gal staining and p16/p21 expression analysis.
Results
In vivo , JKSQW reduced serum creatinine, blood urea nitrogen, proteinuria, and urinary red blood cell counts, alleviated renal pathological injury, decreased SA-β-gal-positive area, and downregulated p16 and p21. Network pharmacology using TCMSP identified 102 active ingredients and 206 targets; intersection with CKD- and aging-related targets yielded 48 overlapping genes, and PPI analysis identified 13 core targets, including AKT1, TNF, PTGS2, MMP9, and TP53. UHPLC-MS/MS identified 1,452 compounds in JKSQW, including 277 blood-absorbed prototypes. Their 980 unique targets were intersected with disease targets, yielding 349 overlapping targets; KEGG enrichment indicated pathways related to cell-cycle regulation, oxidative stress, and fibrosis. Molecular docking showed that oxypaeoniflorin, a characteristic blood-absorbed monoterpene glycoside from Moutan Cortex, bound 12 of 13 core targets, with 8 showing strong binding. Since Moutan Cortex contributed the most predicted targets and oxypaeoniflorin showed broad binding, we isolated MDP-Exo, which attenuated doxorubicin-induced podocyte senescence and downregulated p16 and p21 in vitro .
Conclusion
Collectively, these findings demonstrate that JKSQW alleviates doxorubicin-induced renal senescence and injury. Through integrated network pharmacology and serum UHPLC-MS/MS, we identified the blood-absorbed components and their predicted pathways, with oxypaeoniflorin from Moutan Cortex exhibiting broad binding to core targets and MDP-Exo attenuating podocyte senescence.
Zitieren
APA
Zhang, S., Wang, B., Sun, C., Tian, L., & Zou, R. (2026). Jinkui Shenqi Wan alleviates doxorubicin-induced renal senescence and injury: insights from network pharmacology and serum UHPLC-MS/MS. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.2010658
Vancouver
Zhang S, Wang B, Sun C, Tian L, Zou R. Jinkui Shenqi Wan alleviates doxorubicin-induced renal senescence and injury: insights from network pharmacology and serum UHPLC-MS/MS. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.2010658
BibTeX
@article{Zhang2026,
author = {Zhang, Shan and Wang, Baihui and Sun, Chen and Tian, Limin and Zou, Rong},
title = {Jinkui Shenqi Wan alleviates doxorubicin-induced renal senescence and injury: insights from network pharmacology and serum UHPLC-MS/MS},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.2010658}
}
EUVIMED